GLP1R and diabetes mellitus: Liraglutide (also known commercially as Saxenda®, Victoza®, and Xultophy®) has transcended its original purpose as a GLP-1 receptor analog, initially developed for the treatment of type 2 diabetes mellitus and the prevention of diabetes-related cardiovascular complications [8–10].